Based on the Altimmune Inc stock forecast from 4 analysts, the average analyst target price for Altimmune Inc is USD 19.00 over the next 12 months. Altimmune Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Altimmune Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Altimmune Inc’s stock price was USD 7.15. Altimmune Inc’s stock price has changed by -2.72% over the past week, +3.92% over the past month and +193.03% over the last year.
No recent analyst target price found for Altimmune Inc
No recent average analyst rating found for Altimmune Inc
Company Overview Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Address: 910 Clopper Road, Gaithersburg, MD, United States, 20878 Read Less
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabo...Read More
Frequently Asked Questions About Altimmune Inc (ALT) Stock
Based on ratings from 4 analysts Altimmune Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on ALT's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ALT is USD 19.00 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 12.
ALT stock's Price/Earning ratio is 34.35.
Our analysis grades ALT stock's Price / Earning ratio at F. This means that ALT stock's Price/Earning ratio is above 80% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ALT may be a overvalued for its sector.
The last closing price of ALT's stock was USD 7.15.
The most recent market capitalization for ALT is USD 0.54B.
Based on targets from 4 analysts, the average taret price for ALT is projected at USD 19.00 over the next 12 months.
This means that ALT's stock price may go up by +165.73% over the next 12 months.
We can't find any ETFs which contains Altimmune Inc's stock.
As per our most recent records Altimmune Inc has 59 Employees.
Altimmune Inc's registered address is 910 Clopper Road, Gaithersburg, MD, United States, 20878.
You can get more information about it from Altimmune Inc's website at https://altimmune.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Altimmune Inc (ALT) Stock
Based on ratings from 4 analysts Altimmune Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on ALT's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ALT is USD 19.00 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 12.
ALT stock's Price/Earning ratio is 34.35.
Our analysis grades ALT stock's Price / Earning ratio at F. This means that ALT stock's Price/Earning ratio is above 80% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ALT may be a overvalued for its sector.
The last closing price of ALT's stock was USD 7.15.
The most recent market capitalization for ALT is USD 0.54B.
Based on targets from 4 analysts, the average taret price for ALT is projected at USD 19.00 over the next 12 months.
This means that ALT's stock price may go up by +165.73% over the next 12 months.
We can't find any ETFs which contains Altimmune Inc's stock.
As per our most recent records Altimmune Inc has 59 Employees.
Altimmune Inc's registered address is 910 Clopper Road, Gaithersburg, MD, United States, 20878.
You can get more information about it from Altimmune Inc's website at https://altimmune.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ALT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
